GH Research (GHRS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

GH Research (GHRS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.26

-0.09 (-1.08%)

At close: Jan 14, 2025, 3:59 PM

8.19

-0.85%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.3
Market Cap	429.75M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.79
PE Ratio (ttm)	-10.46
Forward PE	n/a
Analyst	Buy

Ask	9.06
Volume	76,429
Avg. Volume (20D)	72,944
Open	8.36
Previous Close	8.35
Day's Range	8.02 - 8.67
52-Week Range	5.50 - 14.99
Beta	undefined

About GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 25, 2021

Employees 49

Stock Exchange NASDAQ

Ticker Symbol GHRS

Website https://www.ghres.com

Analyst Forecast

According to 3 analyst ratings, the average rating for GHRS stock is "Buy." The 12-month stock price forecast is $39, which is an increase of 372.15% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 months ago · Source

GH Research shares are trading lower. The company ... Unlock content with Pro Subscription

7 months ago · Source

-17.29%

Shares of psychedelics companies are trading lower after an FDA panel, on Tuesday, rejected the approval of MDMA therapy for people with PTSD.

News

1 month ago · zacks.com

Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?

The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana...

2 months ago · marketbeat.com

3 Fast-Growing Stocks Analysts See Doubling in Price

Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside poten...